Pamela Kushner, MD, FAAFP; Nancy Reau, MD; Arun B. Jesudian, MD, and Kimberly Brown, MD, discuss the impact of hepatic encephalopathy (HE) on patients and their families, as well as strategies for improving patient outcomes.
We know that hepatic encephalopathy (HE) is frequent and one of the most devastating complications of advanced liver disease and liver failure, but can we delve into how HE affects the patient and their family? Also, please address how can we improve patient outcomes.
At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.